- Conditions
- Idiopathic Inflammatory Myopathies, Inflammatory Myopathies
- Interventions
- Imvotamab
- Drug
- Lead sponsor
- IGM Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Palo Alto, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–40
of 16
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis
- Interventions
- CNTY-101, IL-2, Lymphodepleting Chemotherapy
- Biological · Drug
- Lead sponsor
- Century Therapeutics, Inc.
- Industry
- Eligibility
- 17 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Sacramento, California • Chicago, Illinois + 3 more
- Conditions
- Dermatomyositis, Idiopathic Inflammatory Myopathies
- Interventions
- Sodium Thiosulfate
- Drug
- Lead sponsor
- National Institute of Environmental Health Sciences (NIEHS)
- NIH
- Eligibility
- 7 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Sporadic Inclusion Body Myositis (sIBM), Idiopathic Inflammatory Myopathies
- Interventions
- Pozelimab/Cemdisiran
- Combination Product
- Lead sponsor
- Austin Neuromuscular Center
- Other
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
- Interventions
- EFG PH20 SC, PBO
- Biological · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 35 more
- Conditions
- Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis, SLE Nephritis, ANCA Associated Vasculitis
- Interventions
- KYV-101, Cyclophosphamide, Fludarabine
- Drug
- Lead sponsor
- David Porter
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA, IIM, Myositis, Scleroderma, Sjogren Syndrome, Sjogrens Disease
- Interventions
- Allogeneic NK Cells
- Drug
- Lead sponsor
- Artiva Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 31
- States / cities
- Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more
- Conditions
- Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, Rheumatoid Arthritis
- Interventions
- CC-97540, Fludarabine, Cyclophosphamide, Tocilizumab
- Drug
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 30
- States / cities
- Aurora, Colorado • Denver, Colorado • New Haven, Connecticut + 19 more
- Conditions
- Polymyositis, Dermatomyositis
- Interventions
- KZR-616, Placebo
- Drug
- Lead sponsor
- Kezar Life Sciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 12
- States / cities
- Beverly Hills, California • Orange, California • Miami, Florida + 9 more
- Conditions
- Polymyositis, Dermatomyositis
- Interventions
- Anifrolumab (blinded), Placebo, Anifrolumab (unblinded, open label)
- Combination Product · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 43
- States / cities
- Phoenix, Arizona • Irvine, California • Aurora, Colorado + 38 more
- Conditions
- Dermatomyositis, Polymyositis, Inclusion Body Myositis
- Interventions
- Not listed
- Lead sponsor
- National Institute of Environmental Health Sciences (NIEHS)
- NIH
- Eligibility
- 2 Years to 100 Years
- Enrollment
- 1,200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 1995
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Bethesda, Maryland • Research Triangle Park, North Carolina + 1 more
- Conditions
- Idiopathic Inflammatory Myopathies
- Interventions
- Rapcabtagene autoleucel, Active Comparator Option
- Biological · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Zephyrhills, Florida • Augusta, Georgia + 7 more
- Conditions
- Myositis
- Interventions
- PF-06823859, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 318 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 47
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 22 more
- Conditions
- SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis, Inflammatory Myopathy, Idiopathic, Myositis, Diffuse Cutaneous Systemic Sclerosis
- Interventions
- CTX112
- Biological
- Lead sponsor
- CRISPR Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 7
- States / cities
- Redwood City, California • Chicago, Illinois • Iowa City, Iowa + 4 more
- Conditions
- Myositis, Dermatomyositis, Polymyositis, Juvenile Dermatomyositis
- Interventions
- Rituximab, Placebo
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 5 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 17 more
- Conditions
- Idiopathic Inflammatory Myositis
- Interventions
- Daxdilimab, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Anaheim, California